Catalyst

Slingshot members are tracking this event:

Celldex (CLDX) Presents Phase 2 Data Evaluating Glembatumumab Vedotin in Metastatic Melanoma

Source Link:
http://ir.celldex.com/releasedetail.cfm?ReleaseID=957068

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CLDX
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Data is expected to be presented at an appropriate medical meeting in the second half of 2016 for a Phase 2 study of glembatumumab vedotin in metastatic melanoma.
http://ir.celldex.co...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 09, 2016
Occurred Source:
http://ir.celldex.com/releasedetail.cfm?ReleaseID=992756
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Glembatumumab Vedotin, Metastatic Melanoma, Gpnmb
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.